The psychopharmacology algorithm project at the harvard south shore program

Psychopharm Review

Volumn 45, Issue 12, 2010, Pages 91-99

  Osser, David N ^a   Dunlop, Lance R ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Cambria County Mental Health/Mental Retardation Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; ANTIDEPRESSANT AGENT; BUSPIRONE; CITALOPRAM; CLONAZEPAM; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; GABAPENTIN; MIRTAZAPINE; NEFAZODONE; PAROXETINE; PHENELZINE; PLACEBO; PREGABALIN; QUETIAPINE; RISPERIDONE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TIAGABINE; VENLAFAXINE;

ALCOHOL ABUSE; ALGORITHM; ANXIETY DISORDER; BIPOLAR I DISORDER; BIPOLAR II DISORDER; CLINICAL GLOBAL IMPRESSION SCALE; COGNITIVE THERAPY; COMORBIDITY; CONSTIPATION; DEPRESSION; DRUG APPROVAL; DRUG DOSE TITRATION; EJACULATION DISORDER; FRACTURE; GASTROINTESTINAL SYMPTOM; GENERALIZED ANXIETY DISORDER; HUMAN; HYPERTENSION; INSOMNIA; MAJOR DEPRESSION; MONOTHERAPY; NAUSEA; NIGHTMARE; OSTEOPOROSIS; POSTTRAUMATIC STRESS DISORDER; PSYCHODYNAMICS; PSYCHOPHARMACOLOGY; PSYCHOPHARMACOTHERAPY; PSYCHOSOCIAL CARE; PSYCHOTHERAPY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEDATION; SIDE EFFECT; SOCIAL PHOBIA; SUBSTANCE ABUSE; TREATMENT DURATION; UPPER GASTROINTESTINAL BLEEDING; WEIGHT; WEIGHT BEARING;

EID: 79951503716     PISSN: 19369255     EISSN: None     Source Type: Trade Journal    
DOI: 10.1097/01.idt.0000391328.04097.1e     Document Type: Review

References (52)

1. Lane C. Shyness: How Normal Behavior Became a Sickness. New Haven, CT: Yale University Press; 2007.
2. Campbell-Sills L, Stein MB. Justifying the diagnostic status of social phobia: a reply to Wakefield, Horwitz, and Schmitz. Can J Psychiatry (Pubitemid 43175510)
3. Akimova E, Lanzenberger R, Kasper S. The serotonin-1A receptor in anxiety disorders. Biol Psychiatry. 2009;66(7):627-635.
4. Irle E, Ruhleder M, Lange C, et al. Reduced amygdalar and hippocampal size in adults with generalized social phobia. J Psychiatry Neurosci. 2010;35(2):126-131.
5. Osser DN, Renner JA, Bayog R. Algorithms for the pharmacotherapy of anxiety disorders in patients with chemical abuse and dependence. Psychiatric Ann. 1999;29:285-301.
6. Stein DJ, Baldwin DS, Bandelow B, et al. A 2010 evidencebased algorithm for the pharmacotherapy of social anxiety disorder. Curr Psychiatry Rep. 2010;12(5):471-477.
7. Knijnik DZ, Blanco C, Salum GA, et al. A pilot study of clonazepam versus psychodynamic group therapy plus clonazepam in the treatment of generalized social anxiety disorder. Eur Psychiatry. 2008;23(8):567-574.
8. Blanco C, Heimberg RG, Schneier FR, et al. A placebo-controlled trial of phenelzine, cognitive behavioral group therapy, and their combination for social anxiety disorder. Arch Gen Psychiatry. 2010;67(3):286-295.
9. Fournier JC, DeRubeis RJ, Hollon SD, et al. Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA.2010;303(1):47-53.
10. Baker DG, Nievergelt CM, Risbrough VB. Post-traumatic stress disorder: emerging concepts of pharmacotherapy. Expert Opin Emerg Drugs. 2009;14(2):251-272.
11. Cascade E, Kalali AH, Kennedy SH. Real-world data on SSRI antidepressant side effects. Psychiatry (Edgmont). 2009;6(2):16-18.
12. Hamoda HM, Osser DN. The Psychopharmacology Algorithm Project at the Harvard South Shore Program: an update on psychotic depression. Harv Rev Psychiatry. 2008;16(4):235-247.
13. Ansari A, Osser DN. The psychopharmacology algorithm project at the Harvard South Shore Program: an update on bipolar depression. Harv Rev Psychiatry. 2010;18(1):36-55.
14. Hedges DW, Brown BL, Shwalb DA. A direct comparison of effect sizes from the Clinical Global Impression-Improvement Scale to effect sizes from other rating scales in controlled trials of adult social anxiety disorder. Hum Psychopharmacol. 2009;24(1):35-40.
15. Oosterbaan DB, van Balkom AJ, Spinhoven P, et al. The placebo response in social phobia. J Psychopharmacol. 2001;15(3):199-203. (Pubitemid 32808255)
16. Fava M, Rush AJ, Alpert JE, et al. Difference in treatment outcome in outpatients with anxious versus nonanxious depression:a STAR*D report. Am J Psychiatry. 2008;165(3):342-351. (Pubitemid 351704490)
17. Suppes T. Is there a role for antidepressants in the treatment of bipolar II depression? Am J Psychiatry. 2010;167(7):738-740.
18. Stein DJ, Stein MB, Pitts CD, et al. Predictors of response to pharmacotherapy in social anxiety disorder: an analysis of 3 placebocontrolled paroxetine trials. J Clin Psychiatry. 2002;63(2):152-155. (Pubitemid 34173853)
19. Stein DJ, Versiani M, Hair T, et al. Efficacy of paroxetine for relapse prevention in social anxiety disorder: a 24-week study. Arch Gen Psychiatry. 2002;59(12):1111-1118. (Pubitemid 35424021)
20. Liebowitz MR, Stein MB, Tancer M, et al. A randomized, double-blind, fixed-dose comparison of paroxetine and placebo in the treatment of generalized social anxiety disorder. J Clin Psychiatry. 2002;63(1):66-74. (Pubitemid 34113490)
21. Serretti A, Chiesa A. Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. J Clin Psychopharmacol. 2009;29(3):259-266.
22. Munoz V, Stravynski A. Social phobia and sexual problems: a comparison of social phobic, sexually dysfunctional and normal individuals. Br J Clin Psychol. 2010;49(Pt 1):53-66.
23. Einarson A, Pistelli A, DeSantis M, et al. Evaluation of the risk of congenital cardiovascular defects associated with use of paroxetine during pregnancy. Am J Psychiatry. 2008;165(6):749-752. (Pubitemid 351810544)
24. Van Ameringen MA, Lane RM, Walker JR, et al. Sertraline treatment of generalized social phobia: a 20-week, double-blind, placebo-controlled study. Am J Psychiatry. 2001;158(2):275-281. (Pubitemid 32116525)
25. Walker JR, Van Ameringen MA, Swinson R, et al. Prevention of relapse in generalized social phobia: results of a 24-week study in responders to 20 weeks of sertraline treatment. J Clin Psychopharmacol. 2000;20(6):636-644.
26. Stein MB, Fyer AJ, Davidson JR, et al. Fluvoxamine treatment of social phobia (social anxiety disorder): a double-blind, placebocontrolled study. Am J Psychiatry. 1999;156(5):756-760. (Pubitemid 29220075)
27. Davidson J, Yaryura-Tobias J, DuPont R, et al. Fluvoxaminecontrolled release formulation for the treatment of generalized social anxiety disorder. J Clin Psychopharmacol. 2004;24:118-125. (Pubitemid 38380834)
28. Westenberg HG, Stein DJ, Yang H, et al. A double-blind placebocontrolled study of controlled release fluvoxamine for the treatment of generalized social anxiety disorder. J Clin Psychopharmacol.2004;24:49-55. (Pubitemid 38134166)
29. Kasper S, Stein DJ, Loft H, et al. Escitalopram in the treatment of social anxiety disorder: randomised, placebo-controlled, flexibledosage study. Br J Psychiatry. 2005;186(3):222-226. (Pubitemid 40343816)
30. Lader M, Stender K, Burger V, et al. Efficacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder: randomised, double-blind, placebo-controlled, fixeddose study. Depress Anxiety. 2004;19(4):241-248. (Pubitemid 39014144)
31. Davidson JR, Foa EB, Huppert JD, et al. Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalized social phobia. Arch Gen Psychiatry. 2004;61(10):1005-1013. (Pubitemid 39336534)
32. Stein DJ, Ipser JC, Balkom AJ. Pharmacotherapy for social phobia. Cochrane Database Syst Rev. 2004;(4):CD001206.
33. de Abajo FJ, Garcia-Rodriguez LA. Risk of upper gastrointestinal tract bleeding associated with selective serotonin reuptake inhibitors and venlafaxine therapy: interaction with nonsteroidal anti-inflammatory drugs and effect of acid-suppressing agents. Arch Gen Psychiatry. 2008;65(7):795-803. (Pubitemid 351957705)
34. Richards JB, Papaioannou A, Adachi JD, et al. Effect of selective serotonin reuptake inhibitors on the risk of fracture. Arch Intern Med. 2007;167(2):188-194. (Pubitemid 46148067)
35. Etminan M, Mikelberg FS, Brophy JM. Selective serotonin reuptake inhibitors and the risk of cataracts: a nested case-control study. Ophthalmology. 2010;117(6):1251-1255.
36. Liebowitz MR, Gelenberg AJ, Munjack D. Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder. Arch Gen Psychiatry. 2005;62(2):190-198. (Pubitemid 40189136)
37. Stein MB, Pollack MH, Bystritsky A, et al. Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial.Psychopharmacology (Berl). 2005;177(3):280-288. (Pubitemid 40137288)
38. Liebowitz MR, Schneier F, Campeas R, et al. Phenelzine vs atenolol in social phobia. A placebo-controlled comparison. Arch Gen Psychiatry. 1992;49(4):290-300.
39. Muehlbacher M, Nickel MK, Nickel C, et al. Mirtazapine treatment of social phobia in women: a randomized, double-blind, placebocontrolled study. J Clin Psychopharmacol. 2005;25(6):580-583. (Pubitemid 41669054)
40. Davidson JR, Potts N, Richichi E, et al. Treatment of social phobia with clonazepam and placebo. J Clin Psychopharmacol. 1993;13(6):423-428. (Pubitemid 24026104)
41. Gelernter CS, Uhde TW, Cimbolic P, et al. Cognitive-behavioral and pharmacological treatments of social phobia. A controlled study. Arch Gen Psychiatry. 1991;48(10):938-945.
42. Hindmarch I. Cognitive toxicity of pharmacotherapeutic agents used in social anxiety disorder. Int J Clin Pract. 2009;63(7):1085-1094.
43. Van Ameringen M, Mancini C, Wilson C. Buspirone augmentation of selective serotonin reuptake inhibitors (SSRIs) in social phobia. J Affect Disord. 1996;39(2):115-121. (Pubitemid 26232803)
44. Trivedi MH, Fava M, Wisniewski SR, et al. Medication augmentation after the failure of SSRIs for depression. N Engl J Med. 2006;354(12):1243-1252.
45. Altamura AC, Pioli R, Vitto M, et al. Venlafaxine in social phobia: a study in selective serotonin reuptake inhibitor non-responders.Int Clin Psychopharmacol. 1999;14(4):239-245. (Pubitemid 29358991)
46. Van Ameringen M, Mancini C, Oakman J, et al. Nefazodone in the treatment of generalized social phobia: a randomized, placebocontrolled trial. J Clin Psychiatry. 2007;68(2):288-295. (Pubitemid 46362651)
47. Pande AC, Davidson JR, Jefferson JW, et al. Treatment of social phobia with gabapentin: a placebo-controlled study. J Clin Psychopharmacol. 1999;19(4):341-348. (Pubitemid 29344848)
48. Vaishnavi S, Alamy S, Zhang W, et al. Quetiapine as monotherapy for social anxiety disorder: a placebo-controlled study. Prog Neuro-Psychopharmacol Biol Psychiatry. 2007;31(7):1464-1469. (Pubitemid 47302561)
49. Ray WA, Chung CP, Murray KT, et al. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med. 2009;360(3):225-235.
50. Simon NM, Hoge EA, Fischmann D, et al. An open-label trial of risperidone augmentation for refractory anxiety disorders. J Clin Psychiatry. 2006;67(3):381-385.
51. Pande AC, Feltner DE, Jefferson JW, et al. Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebocontrolled, multicenter study. J Clin Psychopharmacol. 2004; 24(2):141-149. (Pubitemid 38380837)
52. Dunlop BW, Papp L, Garlow SJ, et al. Tiagabine for social anxiety disorder. Hum Psychopharmacol. 2007;22(4):241-244. (Pubitemid 46939281)